|
Stage of the disease | Phase | Intervention | Trial number |
|
Monotherapy |
|
Recurrence after prior therapy with maintenance BEV | II | BEV monotherapy | NCT00866723 |
|
Combination with chemotherapy |
|
Newly diagnosed | III | Carboplatin and paclitaxel with versus without BEV | ICON7NCT00483782 |
Previously untreated stage III or IV | III | Carboplatin and paclitaxel versus carboplatin, paclitaxel, and concurrent BEV with versus without extended BEV | GOG218NCT00262847 |
Adjuvant | II | Carboplatin, paclitaxel and BEV (BEV omitted in first cycle) | OVCANCT00129727 |
Newly diagnosed stage III/IV | II | Carboplatin, paclitaxel and BEV | AV53206sNCT00127920 |
Newly diagnosed stage IB-IV | II | Oxaliplatin and docetaxel with BEV | TEACONCT00296816 |
Newly diagnosed stage II-III | II | IV paclitaxel, IP cisplatin and IV BEV followed by BEV consolidation | AVF3953NCT00511992 |
Initial treatment of optimal stage II or III (adjuvant) | II | IV and IP paclitaxel, IP cisplatin, and IV BEV | 06-064NCT00588237 |
Platinum-sensitive recurrent | III | Carboplatin and paclitaxel with versus without BEV followed by secondary cytoreduction surgery | GOG213NCT00565851 |
Platinum-sensitive recurrent | III | Carboplatin and gemcitabine with versus without BEV | AVF4095gNCT00434642 |
Platinum-sensitive recurrent | II | Gemcitabine, carboplatin and BEV | 2005CO073NCT00267696 |
Platinum-sensitive recurrent | II | Carboplatin and liposomal doxorubicin plus BEV | CR015094NCT00698451 |
Platinum-sensitive recurrent | II | Oxaliplatin, gemcitabine, and BEV | DF 04-356NCT00418093 |
Recurrent having failed platinum- and taxane-based regimens | II | Pemetrexed and BEV | 08-0508NCT00868192 |
Platinum-resistant recurrent | II | Weekly topotecan with BEV | AVF3648sNCT00343044 |
Platinum-resistant recurrent | II | BEV and docetaxel | MCC-14920NCT00504257 |
Platinum-resistant recurrent | II | BEV and carboplatin | 2008-000878-20NCT00744718 |
Platinum-resistant recurrent | II | BEV and liposomal doxorubicin | AVF3910sNCT00846612 |
Platinum-resistant recurrent | II | Sequential BEV and metronomic cyclophosphamide | 08-148NCT00856180 |
Platinum-resistant recurrent | II | BEV and albumin-bound paclitaxel | ALSSOPR0501NCT00407563 |
2nd or later complete remission, or untreated or refractory to platinum treatment or no response to salvage treatment | II | Stem-cell transplant trial evaluating treatment with BEV plus gemcitabine, docetaxel, melphalan, and carboplatin | 2007-0368NCT00583622 |
Advanced peritoneal carcinomatosis | I | IP oxaliplatin and paclitaxel plus IV paclitaxel and BEV | 2006-1068NCT00491855 |
|
Combination with other targeted therapies |
|
Newly diagnosed | II | BEV and erlotinib as 1st line consolidation chemo after carboplatin, paclitaxel, and BEV induction therapy | 07-039NCT00520013 |
Relapsed or refractory | II | BEV and erlotinib | UARIZ-05-0178-01NCT00696670 |
Recurrent or metastatic | II | BEV and erlotinib | NCI-6759NCT00126542 |
Refractory or recurrent | II | BEV and sorafenib | NCI-07-C-0058NCT00436215 |
Persistent or recurrent | II | BEV with or without everolimus | GOG-0186GNCT00886691 |
|